Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Pediatrix Medical (MD)

Pediatrix Names Mark Ordan CEO; Expects 2024 Adjusted EBITDA at High End or Above

Positive Impact 4 of 5 leadership Written later

Pediatrix Medical Group said Executive Chair Mark S. Ordan will return as chief executive, effective immediately, succeeding James D. Swift, M.D. The company also said it currently believes it will reach the high end of its $205 million to $215 million 2024 adjusted EBITDA outlook and that the result may exceed that range, which would be an upward move from the prior guidance.

Key points

  • Mark S. Ordan appointed CEO effective immediately, succeeding James D. Swift, M.D., who will assist during the transition
  • Prior 2024 adjusted EBITDA outlook was $205 million to $215 million; company now expects the high end or possibly more
  • Fourth quarter and full year 2024 results to be announced February 20, 2025

The filing

CompanyPediatrix Medical (MD)
Form8-K, current report
Filed with the SECJan 13, 2025, 6:50 AM ET
Accession number0001193125-25-004937

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 6:56 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on January 13, 2025.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.